MoneyWorks4Me

Glaxosmithkline Pharmaceuticals informs about analyst meet

15 Feb 2025 Evaluate
Pursuant to Regulation 30 read with Part A of Schedule Ill of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Glaxosmithkline Pharmaceuticals has informed that the recording is uploaded at Audio file – https://india-pharma.gsk.com/media/7833/analysts-meet-audio-recording-14th-feb-2025.mp3 Video file – https://india-pharma.gsk.com/media/7834/analysts-meet-video-recording-14th-feb-2025.mp4.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2980.05 49.55 (1.69%)
25-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1917.00
Dr. Reddys Labs. 1191.00
Cipla 1420.00
Lupin 2175.00
Zydus Lifesciences 1130.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: